OnCo
institutionsInstitution

West Japan Oncology Group

aka WJOG, West Japan Thoracic Oncology Group, WJTOG

Japan's second national cooperative group, born in thoracic oncology; its WJTOG3405 trial helped establish EGFR inhibitors as first-line lung cancer therapy.

Founded in 2000 as the West Japan Thoracic Oncology Group and renamed WJOG in 2008 as it expanded into gastrointestinal, breast and other cancers. WJTOG3405 (gefitinib versus cisplatin-docetaxel in EGFR-mutant NSCLC) was one of the two Japanese phase 3 trials that made EGFR testing and first-line targeted therapy the standard worldwide. WJOG runs investigator-initiated trials of targeted agents, immunotherapy and chemotherapy across Japan's university and cancer centre hospitals and collaborates with JCOG and with Asian and Western groups. Its committees cover thoracic, gastrointestinal, breast, gynaecologic and genitourinary cancers.

Location
Osaka, JP
Type
consortium
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#277 · 24 points (0 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking

Programmes

4top
  • Thoracic oncology (WJTOG3405)
  • Gastrointestinal oncology
  • Breast oncology
  • Investigator-initiated trials of targeted therapy and immunotherapy

Connected

12top

Pages like this

not linked directly; found by shared links